BioVex Wins Clearance to Initiate Phase I Herpes Vaccine Trial
BioVex has announced that the UK Medicines and Healthcare products Regulatory Agency has accepted BioVex’s clinical trial application to conduct a Phase I clinical study testing the safety and immunogenicity of its lead infectious disease candidate for genital herpes, ImmunoVEX HSV2.
ImmunoVEX HSV2 is a novel live-attenuated vaccine which has been rationally designed to remove the genes that allow herpes virus to avoid the immune system. This should allow the immune system to recognize and mount a powerful immune response against the causative agent of genital herpes.
Robert Coffin, founder and chief technology officer of BioVex, said: “We believe that this vaccine, based on a new understanding of herpes simplex virus biology, has the potential to substantially advance the field. Accordingly, today’s news is a significant milestone towards realizing this potential.”